Department of Clinical Pharmacy and Pharmacotherapy Dusseldorf, Germany
Review Article
Pharmacokinetic Modeling: Target for Antidepressant Drug Development
Author(s): James Clae*
Targeting the nicotinic acetylcholine receptor is a crucial new direction in the development of antidepressant drugs (nAChR). This receptor, which is extensively distributed in the areas of the brain connected to depression, is also involved in other significant processes that are connected to depression, including stress and inflammation. Mecamylamine- and cytisine-based compounds can be used as a general classification of the two types of medications that target nAChRs. Strong preclinical outcomes support the antidepressant efficacy of both classes when used in conjunction with other primary antidepressants, and these medications likely exert their effects by antagonistically binding to n.. View More»
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 
